Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 From the Ongoing ...

Oruka Therapeutics drug cleared skin in 64% of psoriasis patients in trial

ORKA-001 also met secondary endpoints at 16 weeks, and updated data support the potential for once-yearly dosing

Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis (2026-04-27)

-Oruka Therapeutics, Inc., a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, today announced positive interim results from its EVERLAST-A Phase 2 a trial of ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody, in moderate-to-severe plaque psoriasis.

Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing ...

MENLO PARK, Calif., April 26, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, today announced it will report…

Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026

MENLO PARK, Calif., April 26, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company...

Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST

MENLO PARK, Calif., April 26, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, today announced it will report Week 16 data for ORKA-001 from the ongoing EVERLAST-A Phase 2a trial in moderate-to-severe plaque psoriasis on Monday, April 27, 2026. Following the announcement, the compa…

Oruka Therapeutics Shares Soar 19% on Positive Week 16 Psoriasis Drug Trial Data

NEW YORK — Oruka Therapeutics Inc. (NASDAQ: ORKA) shares surged nearly 19% Monday to $82.41 in heavy trading after the clinical-stage biotech company reported strongly positive Week 16 interim data from its Phase 2a EVERLAST-A trial of ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody for moderate-to-severe plaque psoriasis.